256 related articles for article (PubMed ID: 28224267)
1. Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas.
Sett A; Borthakur BB; Bora U
Clin Transl Oncol; 2017 Aug; 19(8):976-988. PubMed ID: 28224267
[TBL] [Abstract][Full Text] [Related]
2. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX.
Dastjerdi K; Tabar GH; Dehghani H; Haghparast A
Biotechnol Appl Biochem; 2011; 58(4):226-30. PubMed ID: 21838796
[TBL] [Abstract][Full Text] [Related]
3. Selection of a novel DNA thioaptamer against HER2 structure.
Hu Y; Duan J; Cao B; Zhang L; Lu X; Wang F; Yao F; Zhu Z; Yuan W; Wang C; Yang XD
Clin Transl Oncol; 2015 Aug; 17(8):647-56. PubMed ID: 26022131
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial Screening of DNA Aptamers for Molecular Imaging of HER2 in Cancer.
Zhu G; Zhang H; Jacobson O; Wang Z; Chen H; Yang X; Niu G; Chen X
Bioconjug Chem; 2017 Apr; 28(4):1068-1075. PubMed ID: 28122449
[TBL] [Abstract][Full Text] [Related]
5. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro.
Liu Z; Duan JH; Song YM; Ma J; Wang FD; Lu X; Yang XD
J Transl Med; 2012 Jul; 10():148. PubMed ID: 22817844
[TBL] [Abstract][Full Text] [Related]
6. DNA aptamer probes for detection of estrogen receptor α positive carcinomas.
Sett A; Borthakur BB; Sharma JD; Kataki AC; Bora U
Transl Res; 2017 May; 183():104-120.e2. PubMed ID: 28087261
[TBL] [Abstract][Full Text] [Related]
7. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
Reix N; Malina C; Chenard MP; Bellocq JP; Delpous S; Molière S; Sevrin A; Neuberger K; Tomasetto C; Mathelin C
Breast Cancer Res Treat; 2016 Nov; 160(2):249-259. PubMed ID: 27709352
[TBL] [Abstract][Full Text] [Related]
8. In vitro selection of modified RNA aptamers against CD44 cancer stem cell marker.
Ababneh N; Alshaer W; Allozi O; Mahafzah A; El-Khateeb M; Hillaireau H; Noiray M; Fattal E; Ismail S
Nucleic Acid Ther; 2013 Dec; 23(6):401-7. PubMed ID: 24171482
[TBL] [Abstract][Full Text] [Related]
9. Aptamer selection and applications for breast cancer diagnostics and therapy.
Liu M; Yu X; Chen Z; Yang T; Yang D; Liu Q; Du K; Li B; Wang Z; Li S; Deng Y; He N
J Nanobiotechnology; 2017 Nov; 15(1):81. PubMed ID: 29132385
[TBL] [Abstract][Full Text] [Related]
10. Obtaining and characterization of monoclonal antibodies against recombinant extracellular domain of human epidermal growth factor receptor 2.
Sarina N; Abeldenov S; Turgimbayeva A; Zhylkibayev A; Ramankulov Y; Khassenov B; Eskendirova S
Hum Antibodies; 2018 Feb; 26(2):103-111. PubMed ID: 29036807
[TBL] [Abstract][Full Text] [Related]
11. Selection of an aptamer against mouse GP2 by SELEX.
Hanazato M; Nakato G; Nishikawa F; Hase K; Nishikawa S; Ohno H
Cell Struct Funct; 2014; 39(1):23-9. PubMed ID: 24334484
[TBL] [Abstract][Full Text] [Related]
12. Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy.
Mahlknecht G; Sela M; Yarden Y
Methods Mol Biol; 2015; 1317():3-15. PubMed ID: 26072398
[TBL] [Abstract][Full Text] [Related]
13. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
Aigner A; Juhl H; Malerczyk C; Tkybusch A; Benz CC; Czubayko F
Oncogene; 2001 Apr; 20(17):2101-11. PubMed ID: 11360194
[TBL] [Abstract][Full Text] [Related]
14. Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy.
Jeong HY; Kim H; Lee M; Hong J; Lee JH; Kim J; Choi MJ; Park YS; Kim SC
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371333
[TBL] [Abstract][Full Text] [Related]
15. A human epidermal growth factor receptor 3/heregulin interaction inhibitor aptamer discovered using SELEX.
Yokoyama T; Ando T; Iwamoto R; Fuji D; Yamamoto M; Kawakami T
Biochem Biophys Res Commun; 2021 May; 553():148-153. PubMed ID: 33770580
[TBL] [Abstract][Full Text] [Related]
16. Revealing the molecular interactions of aptamers that specifically bind to the extracellular domain of HER2 cancer biomarker protein: An in silico assessment.
Niazi S; Purohit M; Sonawani A; Niazi JH
J Mol Graph Model; 2018 Aug; 83():112-121. PubMed ID: 29902673
[TBL] [Abstract][Full Text] [Related]
17. A novel molecular marker of breast cancer stem cells identified by cell-SELEX method.
Lu M; Zhou L; Zheng X; Quan Y; Wang X; Zhou X; Ren J
Cancer Biomark; 2015; 15(2):163-70. PubMed ID: 25519016
[TBL] [Abstract][Full Text] [Related]
18. Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity.
Wang DL; Song YL; Zhu Z; Li XL; Zou Y; Yang HT; Wang JJ; Yao PS; Pan RJ; Yang CJ; Kang DZ
Biochem Biophys Res Commun; 2014 Oct; 453(4):681-5. PubMed ID: 25242523
[TBL] [Abstract][Full Text] [Related]
19. Preparation and
Okarvi SM; Aljammaz I
Anticancer Res; 2018 May; 38(5):2823-2830. PubMed ID: 29715105
[TBL] [Abstract][Full Text] [Related]
20. Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX.
Li S; Xu H; Ding H; Huang Y; Cao X; Yang G; Li J; Xie Z; Meng Y; Li X; Zhao Q; Shen B; Shao N
J Pathol; 2009 Jul; 218(3):327-36. PubMed ID: 19291713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
